Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

• Market Cap: ₹127.32B
• Dividend Yield: 0.31%
• Average Volume (3M): 3.75K
• Price to Earnings (P/E): 21.0
• Beta (1Y): 1.42
• Revenue Growth: 11.41%
• EPS Growth: 19.22%
• Country: IN
• Employees: 3,406
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 21.80
• Shares Outstanding: 76,011,696
• 10 Day Avg. Volume: 2,866
• 30 Day Avg. Volume: 3,752
• PEG Ratio: 1.63
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 7.78
• P/FCF Ratio: 62.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 85.1
• Revenue Forecast (FY): ₹22.39B

• Rating: 69 Neutral
• Price Target: ₹1,834.00 ▼(-0.65% Downside)
• Action: Downgraded Date: 09/27/25
• Date: Action: Downgraded 09/27/25

Caplin Point Laboratories' strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and solid profitability. However, technical indicators suggest a bearish trend, and the valuation appears moderately high, which tempers the overall score.

Positive Factors

Differentiated product portfolio

Caplin Point's emphasis on complex dosage forms (injectables, ophthalmics) creates durable competitive advantages: higher technical barriers, stronger pricing versus commoditized generics, and stickier customer relationships in regulated markets, supporting sustained revenue quality.

Sustained revenue growth and margins

Multi-year revenue expansion with robust gross, EBIT and EBITDA margins demonstrates efficient operations and scalable cost structure. Sustained margin profiles imply competitive manufacturing economics and durable profitability across business cycles.

Strong balance sheet and cash generation

Low debt and strong free cash flow generation provide financial flexibility to fund registrations, capacity investments, or tender-backed working capital. This reduces refinancing risk and supports long-term reinvestment and stability.

Negative Factors

Tender-driven revenue volatility

Significant exposure to tender and contract awards creates structural revenue lumpiness and heightened competitive pressure on pricing. Long-term earnings can fluctuate with tender outcomes and contract renewals, weakening predictability of cash flows.

Third-party distribution dependence

Reliance on external distributors and partners for market access increases execution and margin risk over time. Partner performance, renegotiation, or channel disputes can limit market penetration, delay launches, and compress long-term sales visibility.

Concentration in complex dosage forms

Concentration in injectables and ophthalmics raises regulatory, manufacturing complexity and capacity risk. While higher margin, these segments demand sustained capital, quality compliance and supply reliability; failures or regulatory actions would have outsized impact.

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.

How the Company Makes Money

Caplin Point Laboratories generates revenue through multiple streams, primarily from the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has a robust export business, catering to markets across various continents, which significantly contributes to its earnings. Additionally, CAPLIPOINT engages in contract manufacturing for other pharmaceutical companies, providing it with a steady income source. The company also benefits from strategic partnerships and collaborations that enhance its product offerings and market reach. Its revenue model is bolstered by a focus on research and development, allowing it to innovate and expand its product portfolio in response to market demands.

Caplin Point Laboratories Limited Financial Statement Overview

Summary

Caplin Point Laboratories exhibits strong financial health with impressive revenue growth, efficient operations, and solid profitability. The balance sheet is robust with low leverage and high equity, while cash flow generation is ample and sustainable.

Income Statement

Caplin Point Laboratories has demonstrated strong revenue growth, with a significant increase in total revenue over the past five years. The gross profit margin is robust, indicating efficient cost management. Additionally, the EBIT and EBITDA margins highlight strong operational performance, while the net profit margin reflects effective bottom-line management.

Balance Sheet

The company's balance sheet is solid, featuring a low debt-to-equity ratio which suggests prudent financial leverage. The equity ratio is high, showcasing a strong equity position relative to total assets. Return on equity has shown positive trends, reflecting good profitability on shareholders' investments.

Cash Flow

Caplin Point Laboratories has a healthy cash flow, with consistent growth in free cash flow. The operating cash flow to net income ratio indicates strong cash generation relative to net income, supporting business sustainability. The free cash flow to net income ratio is solid, ensuring ample cash availability for reinvestment or debt reduction.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	19.91B	19.40B	16.96B	14.68B	12.71B	10.62B
Gross Profit	11.79B	11.38B	9.40B	7.89B	6.99B	5.82B
EBITDA	6.73B	6.49B	5.51B	4.40B	3.94B	3.28B
Net Income	5.65B	5.36B	4.57B	3.76B	3.00B	2.42B
Balance Sheet
Total Assets	0.00	32.09B	26.98B	21.91B	17.36B	13.64B
Cash, Cash Equivalents and Short-Term Investments	9.03B	9.03B	7.88B	6.50B	5.13B	4.46B
Total Debt	0.00	50.20M	19.70M	54.80M	21.30M	183.92M
Total Liabilities	-28.86B	3.22B	3.51B	2.84B	2.26B	1.60B
Stockholders Equity	28.86B	28.50B	23.16B	18.80B	14.84B	11.86B
Cash Flow
Free Cash Flow	0.00	2.41B	1.73B	779.00M	2.46B	1.95B
Operating Cash Flow	0.00	4.32B	3.18B	2.72B	3.37B	2.66B
Investing Cash Flow	0.00	-3.35B	-3.20B	-2.18B	-3.77B	-294.40M
Financing Cash Flow	0.00	-383.20M	-380.70M	-281.70M	-407.10M	-239.78M

Caplin Point Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1845.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 1845.95 is above the 20-day moving average (MA) of 1751.34, above the 50-day MA of 1797.75, and below the 200-day MA of 1995.99, indicating a bearish trend. The MACD of -29.72 indicates Positive momentum. The RSI at 37.34 is Neutral, neither overbought nor oversold. The STOCH value of 40.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹171.30B	11.37	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹139.43B	25.87	―	0.24%	8.14%	5.18%
CAPLIPOINT	69 Neutral	₹127.32B	21.04	―	0.31%	11.41%	19.22%
NEULANDLAB	67 Neutral	₹168.02B	91.73	―	0.08%	0.34%	-14.13%
APLLTD	60 Neutral	₹138.61B	22.24	―	1.28%	11.42%	-1.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Caplin Point Laboratories Limited Corporate Events

Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic manufacturer, covering an addressable market of $473.2 million for the year ended August 2025. The deal strengthens Caplin’s U.S. portfolio—now including select oncology injectables to be commercialized from its new oncology facility in Kakkalur—and supports its strategy to deepen presence in the U.S. while progressively rolling out these products to key non-U.S. markets such as Mexico, Canada, the European Union and Brazil, reinforcing the company’s positioning as a growing global player in sterile and oncology generics.

Caplin Steriles Secures USFDA Approval for Acetaminophen Injection

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received USFDA approval for its Acetaminophen Injection in single-dose infusion bags. This approval marks a significant milestone for Caplin Steriles, allowing it to offer a generic equivalent of a drug with substantial market sales in the US, potentially enhancing its market position and expanding its product offerings in the US pharmaceutical market.